Shots: The companies collaborated to develop cell line, drug substance, and drug product manufacturing of therapeutic and diagnostic mAbs directed against the immuno-oncology target oxMIF for the treatment of multiple […]readmore
Shots: The companies collaborated for CDx development of tepotinib in mainland China. The CDx test is based on Burning Rock’s OncoCompass target which is a self-developed NGS-based liquid biopsy solution […]readmore
Shots: LCB to receive up front & milestone of ~$1027.5M upon achievement of development & regulatory milestones along with royalties on net sales. The deals also include ~$29.5M in upfront […]readmore
Shots: Entos will use its Fusogenix nucleic acid delivery system to develop BioMarin products for multiple genetic diseases. BioMarin will be responsible for the preclinical studies of the Fusogenix-formulated products […]readmore
Shots: Secarna to receive an upfront along with an option exercise fees & is also eligible to receive development & commercial milestone along with royalties on net sales of personalized […]readmore
Shots: This agreement will expand Mustang’s pipeline of ex vivo lentiviral gene therapies for the treatment of SCID Lentiviral gene therapy is currently being evaluated in a P-I/II clinical trial […]readmore
Shots: Dunad to receive $24M up front, equity investment, research funding & is eligible to receive ~$1.3B milestones along with royalties & will also be responsible for program execution up […]readmore
Shots: Metagenomi to receive an up front, equity investment & is eligible to receive target option exercise fees in addition to development, regulatory, and commercial milestones along with royalties on […]readmore
Shots: Synthekine to receive up front along with an additional one-time payment, if selects a second target & will be eligible for ~$525M in development, regulatory, and commercialization milestones along […]readmore
Shots: Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close in Q1’22 The acquisition follows […]readmore